Stockholm, Sweden
Stockholm, Sweden

Time filter

Source Type

News Article | February 15, 2017
Site: www.chromatographytechniques.com

Every year, thousands of scientists, researchers and laboratory enthusiasts descend on The Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy (Pittcon) to get a glimpse of the year’s newest technologies and innovations. It’s the perfect place for such a thing given Pittcon’s annual attendance of nearly 13,000 persons from 90 different countries. Pittcon has something for everyone. Exhibitors, or laboratory equipment manufacturers, can highlight their newest instrumentation to a highly interested target audience. Consider these numbers from Pittcon 2016: 75 percent of attendees are involved in the purchasing process, while 50 percent planned to make a purchase within 6 months. The same excitement is present for conferees, who are on the receiving end of the latest and greatest products, technologies and solutions. The enormity of the conference also lends itself to great networking opportunities and professional development courses. And let’s not forget about the press—Pittcon attracts nearly 200 global journalists representing more than 70 publications, including myself and my colleagues here at Laboratory Equipment. My favorite thing about attending Pittcon as a journalist is the wealth of important information I collect to be disseminated not only immediately, but throughout the rest of the year as well. Held annually in the first or second week of March, Pittcon sets the tone for the lab industry for the next 365 days. Whatever trends I see and report on in Chicago on March 5 to 9 will reverberate until Pittcon 2018.


THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES Valens GroWorks Corp. (CSE:VGW) (the "Company") is pleased to announce entering into two letters of intent (each, an "LOI") in pursuit of its farm to pharma objectives. Each LOI outlines the general terms and conditions of a proposed arms-length transaction pursuant to which the Company completes a corporate acquisition, the highlights of which are presented below, subject to entering into a definitive Share Exchange Agreement ("SEA") between the parties. The proposed transactions (the "Acquisitions") complement the Company's anticipated receipt of a Controlled Drugs and Substances Dealer's Licence following last month's final inspection by the Regional Inspectorate of the Office of Controlled Substances of Health Canada, and accelerates the Company's path to achieve sustainable cash flow. The Acquisitions are expected to close concurrently with a minimum $5,000,000 funding, the terms and conditions of which will be finalized in due course. The Acquisitions are subject to regulatory approval and standard closing conditions, including the approval of the SEAs by the directors of the respective parties and completion of due diligence investigations to the satisfaction of each of the parties, as well as the conditions highlighted below. In conjunction with the Acquisitions, the Company is pleased to announce the appointment of Dr. Rob O'Brien as President and Chief Science Officer (CSO) of Valens Agritech Ltd., the Company's wholly-owned subsidiary (further described below). Dr. O'Brien holds a PhD from Carleton University where he conducted research at the Chemical Metrology group of the National Research Council. He was a professor in Analytical Chemistry for more than 13 years, developing numerous graduate and undergraduate courses in Advanced Analytical Instrumentation techniques and Forensic Chemistry. Dr. O'Brien is an expert in analytical instrumentation and has set up a number of advanced analytical laboratories. Dr. O'Brien was also the founder of Supra Research and Development, the first spin off company from the UBC Okanagan campus, created to commercialize innovative biomass extraction technology. Over his career, Dr. O'Brien has secured well over $3 million dollars in research grants and has an extensive network of research collaborators. Trading in the common shares of the Company have been halted at the Company's request to allow market review of the disclosure herein, and is expected to resume upon regulatory clearance. Acquisition of 80% of Island Green Cure Ltd. ("IGC") Acquisition of 100% of Supra THC Services Inc. ("SUPRA") Proceeds of a proposed minimum $5,000,000 funding are expected to be allocated as follows: There can be no assurance that the Acquisitions or the proposed financing will be completed as proposed or at all. Further details about the Acquisitions, the proposed financing, and the combined entity will be provided in a comprehensive press release when the parties enter into a SEA. The Canadian Securities Exchange has in no way passed upon the merits of the Acquisitions and has neither approved nor disapproved the contents of this press release. Valens GroWorks Corp is a Canadian Securities Exchange listed company. Its wholly owned subsidiary, Valens Agritech Ltd. ("VAL"), is a post-inspection applicant awaiting the granting of a Controlled Drugs and Substances Dealer's Licence for the cultivation and processing of marijuana (such as creating extracts or derivatives) for the purpose of research, for processing manufacturing derivatives, and for transporting product to other locations (including related packaging, possession, sale, delivery and research activities). VAL is based in the Okanagan Valley of British Columbia, focused on cannabis cultivation and research, with assets and improvements that include a state-of-the-art 17,000 square foot R&D facility. Post-licensing, VAL anticipates participation in clinical trial programs researching the efficacy of medical cannabis for certain indications, and seeks to capture a broad spectrum of medical marijuana users, as well as recreational users once legalized, in pursuit of its ambitious farm to pharma objectives. On behalf of the Board of Directors, This news release contains forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Examples of such statements include statements regarding the use of proceeds from a proposed funding. Information pertaining to SUPRA was prepared and provided by SUPRA for inclusion in this press release. Information pertaining to IGC was prepared and provided by IGC for inclusion in this press release. Such forward-looking statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to: the ability to obtain any necessary financing; the economy generally; competition; regulation and anticipated and unanticipated costs and delays. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation. Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. We seek safe harbor.


MIAMI, Feb. 16, 2017 (GLOBE NEWSWIRE) -- The Female Health Company / Veru Healthcare (NASDAQ:FHCO) today announced the appointment of Matthew C. Gosnell, Ph.D., as Senior Vice President of Manufacturing, Preclinical and Pharmaceutical Development, effective February 15, 2017.  Gosnell has a Ph.D. in analytical chemistry and more than 20 years of experience in pharmaceutical manufacturing, development and sourcing.  His experience ranges from preclinical and investigational new drugs (INDs) through 505(b)(2) and 505(b)(1) New Drug Applications (NDAs) and commercialization.  He will be responsible for identifying clinical and commercial manufacturing partners, chemical synthesis and process scale up development, development and clinical trial materials manufacturing and processes, documentation and submissions related to chemistry, manufacturing and control. “An accomplished scientist and drug developer, Dr. Gosnell brings hands-on experience in strategic planning and execution of process development and manufacturing of both early and late stage drug products,” said Mitchell Steiner, M.D., President and Chief Executive Officer of The Female Health Company / Veru Healthcare.  “He has extensive knowledge and expertise in leading multiple projects in various stages of development and identifying and managing new drug manufacturing sites for clinical development and commercial supply.  Over his career, Dr. Gosnell has made significant contributions to several 505(b)(2) and 505(b)(1) NDAs including Celebrex®, Risperdal® Consta® and Vivitrol® and served in senior level positions with GTx, Alkermes, Pharmacia, McNeil Specialty Products (a division of Johnson & Johnson) and Miles (a unit of Bayer AG).” Prior to joining the Company, Dr. Gosnell served as Senior Director, Product Development and Analytical Sciences for GTx, Inc., where he advanced multiple drug candidates into successive clinical stages of development.  Earlier in his career, he was Director, Quality Technical Services (Analytical Development and Stability) for Alkermes, Inc., Analytical Team Leader for Pharmacia Research and Development and Senior Scientist at McNeil Specialty Products Company.  Dr. Gosnell began his career as Scientist with Miles, Inc., after earning a Doctoral degree in Analytical Chemistry from Oklahoma State University and a Bachelor of Science degree in Chemistry and Mathematics-Computer Science from Manchester College. About The Female Health Company / Veru Healthcare The Female Health Company / Veru Healthcare is a pharmaceutical and medical device company, with a focus on the development and commercialization of pharmaceuticals that qualify for the FDA's 505(b)(2) accelerated regulatory approval pathway as well as the 505(b)(1) pathway.  The Company does business both as "Veru Healthcare" and as "The Female Health Company" and is organized as follows: More information about the Female Health Company and its products can be found at www.femalehealth.com, www.veruhealthcare.com and www.femalecondom.org.  For corporate and investor-related information about the Company, please visit www.FHCinvestor.com.


News Article | February 15, 2017
Site: astrobiology.com

A simple chemistry method could vastly enhance how scientists search for signs of life on other planets. The test uses a liquid-based technique known as capillary electrophoresis to separate a mixture of organic molecules into its components. It was designed specifically to analyze for amino acids, the structural building blocks of all life on Earth. The method is 10,000 times more sensitive than current methods employed by spacecraft like NASA's Mars Curiosity rover, according to a new study published in Analytical Chemistry. The study was carried out by researchers from NASA's Jet Propulsion Laboratory, Pasadena, California. One of the key advantages of the authors' new way of using capillary electrophoresis is that the process is relatively simple and easy to automate for liquid samples expected on ocean world missions: it involves combining a liquid sample with a liquid reagent, followed by chemical analysis under conditions determined by the team. By shining a laser across the mixture -- a process known as laser-induced fluorescence detection -- specific molecules can be observed moving at different speeds. They get separated based on how quickly they respond to electric fields. While capillary electrophoresis has been around since the early 1980s, this is the first time it has been tailored specifically to detect extraterrestrial life on an ocean world, said lead author Jessica Creamer, a postdoctoral scholar at JPL. "Our method improves on previous attempts by increasing the number of amino acids that can be detected in a single run," Creamer said. "Additionally, it allows us to detect these amino acids at very low concentrations, even in highly salty samples, with a very simple 'mix and analyze' process." The researchers used the technique to analyze amino acids present in the salt-rich waters of Mono Lake in California. The lake's exceptionally high alkaline content makes it a challenging habitat for life, and an excellent stand-in for salty waters believed to be on Mars, or the ocean worlds of Saturn's moon Enceladus and Jupiter's moon Europa. The researchers were able to simultaneously analyze 17 different amino acids, which they are calling "the Signature 17 standard." These amino acids were chosen for study because they are the most commonly found on Earth or elsewhere. "Using our method, we are able to tell the difference between amino acids that come from non-living sources like meteorites versus amino acids that come from living organisms," said the project's principal investigator, Peter Willis of JPL. Key to detecting amino acids related to life is an aspect known as "chirality." Chiral molecules such as amino acids come in two forms that are mirror images of one another. Although amino acids from non-living sources contain approximately equal amounts of the "left" and "right"-handed forms, amino acids from living organisms on Earth are almost exclusively the "left-handed" form. It is expected that amino acid life elsewhere would also need to "choose" one of the two forms in order to create the structures of life. For this reason, chirality of amino acids is considered one of the most powerful signatures of life. "One of NASA's highest-level objectives is the search for life in the universe," Willis said. "Our best chance of finding life is by using powerful liquid-based analyses like this one on ocean worlds."


VANCOUVER, BC / ACCESSWIRE / February 24, 2017 / Larry W. Reaugh, President and Chief Executive Officer of American Manganese Inc. ("American Manganese" or "AMI" or the "Company") (TSX-V: AMY; OTC PINK: AMYZF; FSE: 2AM), is pleased to announce that the Company and Kemetco Research Inc. will be presenting on advanced battery recycling for Li-Cobalt recovery and reuse at the 24th Cobalt Development Institute (CDI) Conference on May 18 in Marrakech, Morocco. The CDI is a non-profit trade association composed of producers, users, recyclers, and traders of cobalt. They promote the sustainable and responsible production and use of cobalt in all its forms. The Cobalt Conference is an annual event organized by the cobalt industry through the CDI. See CDI. The conference will be attended by Mr. Norman Chow, President of Kemetco Research Inc., and Mr. Larry Reaugh, President and Chief Executive Officer of American Manganese Inc. Mr. Chow will make a technical presentation about American Manganese Inc.'s patent pending process for recycling cathode material such as lithium, cobalt and nickel from spent electric vehicle lithium ion batteries. "The Company is honored to be invited to its second major technical presentation for its lithium ion electric vehicle battery recycling process technology. AMI is being recognized as a significant potential player in the supply of cathode materials specifically cobalt, which is in short supply currently trading at $48,000/tonne," says Mr. Reaugh. Kemetco Research is a private sector integrated science, technology and innovation company. Their Contract Sciences operation provides laboratory analysis and testing, field work, bench scale studies, pilot plant investigations, consulting services, applied research and development for both industry and government. Their clients range from start-up companies developing new technologies through to large multinational corporations with proven processes. They provide scientific expertise in the fields of Specialty Analytical Chemistry, Chemical Process, and Extractive Metallurgy. Because Kemetco carries out research in many different fields, it is able to offer a broader range of backgrounds and expertise than most laboratories. American Manganese Inc. is a diversified specialty and critical metal company focused on capitalizing on its patented intellectual property through low cost production or recovery of electrolytic manganese products throughout the world, and recycling of spent electric vehicle lithium ion rechargeable batteries. Interest in the Company's patented process has adjusted the focus of American Manganese Inc. toward the examination of applying its patented technology for other purposes and materials. American Manganese Inc. aims to capitalize on its patented technology and proprietary know-how to become and industry leader in the recycling of spent electric vehicle lithium ion batteries having cathode chemistries such as: Lithium-Cobalt, Lithium-Cobalt-Nickel-Manganese, and Lithium-Manganese (Please see the Company's January 19, 2017 press release for further details). Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain "forward-looking statements," which are statements about the future based on current expectations or beliefs. For this purpose, statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements by their nature involve risks and uncertainties, and there can be no assurance that such statements will prove to be accurate or true. Investors should not place undue reliance on forward-looking statements. The Company does not undertake any obligation to update forward-looking statements except as required by law. VANCOUVER, BC / ACCESSWIRE / February 24, 2017 / Larry W. Reaugh, President and Chief Executive Officer of American Manganese Inc. ("American Manganese" or "AMI" or the "Company") (TSX-V: AMY; OTC PINK: AMYZF; FSE: 2AM), is pleased to announce that the Company and Kemetco Research Inc. will be presenting on advanced battery recycling for Li-Cobalt recovery and reuse at the 24th Cobalt Development Institute (CDI) Conference on May 18 in Marrakech, Morocco. The CDI is a non-profit trade association composed of producers, users, recyclers, and traders of cobalt. They promote the sustainable and responsible production and use of cobalt in all its forms. The Cobalt Conference is an annual event organized by the cobalt industry through the CDI. See CDI. The conference will be attended by Mr. Norman Chow, President of Kemetco Research Inc., and Mr. Larry Reaugh, President and Chief Executive Officer of American Manganese Inc. Mr. Chow will make a technical presentation about American Manganese Inc.'s patent pending process for recycling cathode material such as lithium, cobalt and nickel from spent electric vehicle lithium ion batteries. "The Company is honored to be invited to its second major technical presentation for its lithium ion electric vehicle battery recycling process technology. AMI is being recognized as a significant potential player in the supply of cathode materials specifically cobalt, which is in short supply currently trading at $48,000/tonne," says Mr. Reaugh. Kemetco Research is a private sector integrated science, technology and innovation company. Their Contract Sciences operation provides laboratory analysis and testing, field work, bench scale studies, pilot plant investigations, consulting services, applied research and development for both industry and government. Their clients range from start-up companies developing new technologies through to large multinational corporations with proven processes. They provide scientific expertise in the fields of Specialty Analytical Chemistry, Chemical Process, and Extractive Metallurgy. Because Kemetco carries out research in many different fields, it is able to offer a broader range of backgrounds and expertise than most laboratories. American Manganese Inc. is a diversified specialty and critical metal company focused on capitalizing on its patented intellectual property through low cost production or recovery of electrolytic manganese products throughout the world, and recycling of spent electric vehicle lithium ion rechargeable batteries. Interest in the Company's patented process has adjusted the focus of American Manganese Inc. toward the examination of applying its patented technology for other purposes and materials. American Manganese Inc. aims to capitalize on its patented technology and proprietary know-how to become and industry leader in the recycling of spent electric vehicle lithium ion batteries having cathode chemistries such as: Lithium-Cobalt, Lithium-Cobalt-Nickel-Manganese, and Lithium-Manganese (Please see the Company's January 19, 2017 press release for further details). Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain "forward-looking statements," which are statements about the future based on current expectations or beliefs. For this purpose, statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements by their nature involve risks and uncertainties, and there can be no assurance that such statements will prove to be accurate or true. Investors should not place undue reliance on forward-looking statements. The Company does not undertake any obligation to update forward-looking statements except as required by law.


VANCOUVER, BC / ACCESSWIRE / February 24, 2017 / Larry W. Reaugh, President and Chief Executive Officer of American Manganese Inc. ("American Manganese" or "AMI" or the "Company") (TSX-V: AMY; OTC PINK: AMYZF; FSE: 2AM), is pleased to announce that the Company and Kemetco Research Inc. will be presenting on advanced battery recycling for Li-Cobalt recovery and reuse at the 24th Cobalt Development Institute (CDI) Conference on May 18 in Marrakech, Morocco. The CDI is a non-profit trade association composed of producers, users, recyclers, and traders of cobalt. They promote the sustainable and responsible production and use of cobalt in all its forms. The Cobalt Conference is an annual event organized by the cobalt industry through the CDI. See CDI. The conference will be attended by Mr. Norman Chow, President of Kemetco Research Inc., and Mr. Larry Reaugh, President and Chief Executive Officer of American Manganese Inc. Mr. Chow will make a technical presentation about American Manganese Inc.'s patent pending process for recycling cathode material such as lithium, cobalt and nickel from spent electric vehicle lithium ion batteries. "The Company is honored to be invited to its second major technical presentation for its lithium ion electric vehicle battery recycling process technology. AMI is being recognized as a significant potential player in the supply of cathode materials specifically cobalt, which is in short supply currently trading at $48,000/tonne," says Mr. Reaugh. Kemetco Research is a private sector integrated science, technology and innovation company. Their Contract Sciences operation provides laboratory analysis and testing, field work, bench scale studies, pilot plant investigations, consulting services, applied research and development for both industry and government. Their clients range from start-up companies developing new technologies through to large multinational corporations with proven processes. They provide scientific expertise in the fields of Specialty Analytical Chemistry, Chemical Process, and Extractive Metallurgy. Because Kemetco carries out research in many different fields, it is able to offer a broader range of backgrounds and expertise than most laboratories. American Manganese Inc. is a diversified specialty and critical metal company focused on capitalizing on its patented intellectual property through low cost production or recovery of electrolytic manganese products throughout the world, and recycling of spent electric vehicle lithium ion rechargeable batteries. Interest in the Company's patented process has adjusted the focus of American Manganese Inc. toward the examination of applying its patented technology for other purposes and materials. American Manganese Inc. aims to capitalize on its patented technology and proprietary know-how to become and industry leader in the recycling of spent electric vehicle lithium ion batteries having cathode chemistries such as: Lithium-Cobalt, Lithium-Cobalt-Nickel-Manganese, and Lithium-Manganese (Please see the Company's January 19, 2017 press release for further details). Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain "forward-looking statements," which are statements about the future based on current expectations or beliefs. For this purpose, statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements by their nature involve risks and uncertainties, and there can be no assurance that such statements will prove to be accurate or true. Investors should not place undue reliance on forward-looking statements. The Company does not undertake any obligation to update forward-looking statements except as required by law.


"We hope our new technique will allow a more rapid detection and intervention for schizophrenia, and ultimately lead to better outcomes," said Gregory Payne, one of the authors and a joint professor with UMD's Fischell Department of Bioengineering (BIOE) and the Institute for Bioscience and Biotechnology Research (IBBR). Schizophrenia is a chronic, severe mental disorder that affects approximately one percent of the U.S. adult population and influences how a person thinks, feels, and behaves. The onset of symptoms usually begins between ages 16 and 30. Symptoms can range from visual and auditory hallucinations and movement disorders to difficulty beginning and sustaining activities. Currently, diagnosing schizophrenia and similar disorders requires a thorough psychological evaluation and a comprehensive medical exam to rule out other conditions. A patient may be evaluated for six or more months before receiving a diagnosis and beginning treatment, particularly if he or she shows only early signs of the disorder. Recent studies have indicated that patient outcomes could be improved if the time elapsed between the onset of symptoms and the initiation of treatment is much shorter. For this reason, researchers believe a chemical test that could detect oxidative stress in the blood—a state commonly linked with schizophrenia and other psychiatric disorders—could be invaluable in helping to diagnose schizophrenia more quickly. The UMD and UMB team, led by research associate Eunkyoung Kim, used a discovery-driven approach based on the assumptions that chemical biomarkers relating to oxidative stress could be found in blood, and that they could be measured by common electrochemical instruments. Building on an understanding of how foods are tested for antioxidants, an iridium salt was used to probe blood serum samples for detectable optical and electrochemical signals that indicate oxidative stress in the body. The promising initial tests have shown various biological reductants can be detected, including glutathione, the most prominent antioxidant in the body. The group worked with professor of psychiatry Deanna Kelly and her team at the Maryland Psychiatric Research Center, University of Maryland School of Medicine, to perform an initial clinical evaluation using serum samples from 10 clinical research study participants who had been diagnosed with schizophrenia, and a healthy control group. Using the new testing method, the research group was able to correctly differentiate the samples of those who had been diagnosed with schizophrenia from those who had no history of the disorder. "Much emerging data suggests that schizophrenia and other psychiatric disorders may be due, in part, to inflammation and oxidative stress abnormalities," Kelly said. "Current methods for measuring these potential biomarkers are not standardized and have many flaws. Our team is excited to work with our collaborators at the University of Maryland to help develop a technique that can more globally measure these outcomes. Being able to have a subjective marker for clinical response or aid in more prompt diagnosis could be revolutionary." More information: Eunkyoung Kim et al, Redox Probing for Chemical Information of Oxidative Stress, Analytical Chemistry (2017). DOI: 10.1021/acs.analchem.6b03620


News Article | February 23, 2017
Site: www.PR.com

Gamry Instruments has created a complete Laboratory Course in Electrochemistry designed to introduce electrochemistry techniques in one semester. Warminster, PA, February 23, 2017 --( In the past all necessary equipment needed to support the study of electrochemistry was purchased from several different vendors. This ground-breaking Laboratory Course in Electrochemistry offers everything needed to complete the experiments designed in the Lab Manual. All data-collection, analysis, and questions are on pages separate from the background and procedure so they can be torn out from the book and handed in with graphs and plots that the student generates. The corresponding Instructor’s Manual includes the desired data analysis. Cynthia A. Schroll, co-author of Introduction to Experimental Electrochemistry and Product Marketing Specialist at Gamry Instruments, stated, “Here at Gamry Instruments we recognize that electrochemistry is a large market from biosensors, like glucose meters, to degradation of infrastructure, like corrosion of bridges and railways, and yet the teaching of this science rarely goes beyond redox reactions and the Nernst Equation in General Chemistry. This lack of education has left students and professionals ill-prepared to tackle these and future challenges. To cover this gap we have developed the Laboratory Course in Electrochemistry to help students by introducing them to the most useful research techniques for application areas such as Analytical Chemistry, Biosensors, and Corrosion Science. We are excited by this opportunity to impact the generation of scientists who will be facing our next great challenges.” A new website, echem101.gamry.com, has been created for this course kit with details of what’s included. Users can download sample experiments featured in the included Lab Manual, view a complete list of what Gamry Instruments supplies with the course, a Course Overview, and you can view a video to learn more about the course. Gamry Instruments has been creating electrochemical instrumentation since 1989. Their simple goal is for every user to be satisfied with their Gamry Instrument. It’s the people at Gamry that truly make the difference with their support staff of electrochemists who are always available to discuss applications and assist with data analysis. For more information on the revolutionary Laboratory Course in Electrochemistry, please visit echem101.gamry.com or contact Cynthia A. Schroll at 215.682.9330, Ext 157. Warminster, PA, February 23, 2017 --( PR.com )-- Gamry Instruments has introduced a full semester Electrochemistry Course, the first of its kind in the industry. Gamry’s Laboratory Course in Electrochemistry includes everything needed to introduce the undergraduate to present–day techniques of modern electrochemistry. The course consists of all specialized electrochemical instrumentation and accessories necessary to run the experiments presented in the included lab manual and to set up a complete electrochemistry laboratory for the course.In the past all necessary equipment needed to support the study of electrochemistry was purchased from several different vendors. This ground-breaking Laboratory Course in Electrochemistry offers everything needed to complete the experiments designed in the Lab Manual. All data-collection, analysis, and questions are on pages separate from the background and procedure so they can be torn out from the book and handed in with graphs and plots that the student generates. The corresponding Instructor’s Manual includes the desired data analysis.Cynthia A. Schroll, co-author of Introduction to Experimental Electrochemistry and Product Marketing Specialist at Gamry Instruments, stated, “Here at Gamry Instruments we recognize that electrochemistry is a large market from biosensors, like glucose meters, to degradation of infrastructure, like corrosion of bridges and railways, and yet the teaching of this science rarely goes beyond redox reactions and the Nernst Equation in General Chemistry. This lack of education has left students and professionals ill-prepared to tackle these and future challenges. To cover this gap we have developed the Laboratory Course in Electrochemistry to help students by introducing them to the most useful research techniques for application areas such as Analytical Chemistry, Biosensors, and Corrosion Science. We are excited by this opportunity to impact the generation of scientists who will be facing our next great challenges.”A new website, echem101.gamry.com, has been created for this course kit with details of what’s included. Users can download sample experiments featured in the included Lab Manual, view a complete list of what Gamry Instruments supplies with the course, a Course Overview, and you can view a video to learn more about the course.Gamry Instruments has been creating electrochemical instrumentation since 1989. Their simple goal is for every user to be satisfied with their Gamry Instrument. It’s the people at Gamry that truly make the difference with their support staff of electrochemists who are always available to discuss applications and assist with data analysis.For more information on the revolutionary Laboratory Course in Electrochemistry, please visit echem101.gamry.com or contact Cynthia A. Schroll at 215.682.9330, Ext 157. Click here to view the list of recent Press Releases from Gamry Instruments


News Article | February 24, 2017
Site: www.eurekalert.org

A study from Stockholm University have now established what was previously suspected, that the high levels of brominated flame retardants measured in cats are from the dust in our homes. The study has been published in the journal Environmental Science & Technology. The study shows that cats are exposed to chemicals found in electronics and furniture, chemicals that become dust and can adversely affect health. It is the first time that this connection has been verified. In a previous study, the researchers demonstrated that brominated flame retardants were found in higher concentrations in the blood of cats that had developed Feline hyperthyroidism (hyperthyroidism in cats) compared to healthy cats. Now, new measurements of healthy cats establish their dust exposure. Paired samples were taken from the same household, i.e. they took both dust samples and blood samples at the same time. "By taking paired samples, we have greater insight into the environment that the cats live in. Moreover the cats in the study spent the majority of their time indoors and therefore air and dust in the home is expected to contribute more than the outdoor environment", says Jana Weiss at the Department of Environmental Science and Analytical Chemistry, Stockholm University. The results are very interesting because small children, notorious for putting everything in their mouths, have exposures to these chemicals similar to cats. "The brominated flame retardants that have been measured in cats are known endocrine disruptors. It's particularly serious when small children ingest these substances because exposure during the development can have consequences later in life, such as thyroid disease", says Jana Weiss. Brominated flame retardants are added to textiles, furniture and electronic equipment to prevent the material from igniting. Many of the brominated flame retardants have been found to be health hazards, and some are suspected endocrine disruptors. A number of them have been prohibited for these reasons in products like electronic goods. However, they are extremely persistent and can leach from the products for many years after they have been produced, ultimately becoming part of dust. The researchers took blood samples from cats and gathered dust in the children's room, the adults' bedroom and the living room. The samples were then analysed for brominated and chlorinated contaminants. The researchers found not only those that are currently in use, but also chemicals that have been banned for decades. The article Cats' Internal Exposure to Selected Brominated Flame Retardants and Organochlorines Correlated to House Dust and Cat Food can be read here: http://pubs. The study is part of an ongoing project called MiSSE (Mixture Assessment of Endocrine Disrupting Compounds). The project aims to identify and evaluate the mix of endocrine disruptors we have in our indoor environment. The project will have a final conference in Stockholm on November 29, 2017 where all results will be presented and discussed. Jana Weiss, scientific coordinator of the project MiSSE, Department of Environmental Science and Analytical Chemistry at Stockholm University, e-mail jana.weiss@aces.su.se.


News Article | February 24, 2017
Site: phys.org

The study shows that cats are exposed to chemicals found in electronics and furniture, chemicals that become dust and can adversely affect health. It is the first time that this connection has been verified. In a previous study, the researchers demonstrated that brominated flame retardants were found in higher concentrations in the blood of cats that had developed Feline hyperthyroidism (hyperthyroidism in cats) compared to healthy cats. Now, new measurements of healthy cats establish their dust exposure. Paired samples were taken from the same household, i.e. they took both dust samples and blood samples at the same time. "By taking paired samples, we have greater insight into the environment that the cats live in. Moreover the cats in the study spent the majority of their time indoors and therefore air and dust in the home is expected to contribute more than the outdoor environment", says Jana Weiss at the Department of Environmental Science and Analytical Chemistry, Stockholm University. The results are very interesting because small children, notorious for putting everything in their mouths, have exposures to these chemicals similar to cats. "The brominated flame retardants that have been measured in cats are known endocrine disruptors. It's particularly serious when small children ingest these substances because exposure during the development can have consequences later in life, such as thyroid disease", says Jana Weiss. Brominated flame retardants are added to textiles, furniture and electronic equipment to prevent the material from igniting. Many of the brominated flame retardants have been found to be health hazards, and some are suspected endocrine disruptors. A number of them have been prohibited for these reasons in products like electronic goods. However, they are extremely persistent and can leach from the products for many years after they have been produced, ultimately becoming part of dust. Explore further: Flame retardants could contribute to hyperthyroidism in older cats

Loading Analytical Chemistry collaborators
Loading Analytical Chemistry collaborators